Business Description
Neuphoria Therapeutics Inc. is an Australian clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with its most advanced drug candidate, BNC210, currently in Phase 2b trials for post-traumatic stress disorder and social anxiety disorder. The company also has oncology assets in its pipeline, including BNC101 and BNC105, alongside earlier-stage programs targeting schizophrenia and autism spectrum disorders. Neuphoria works alongside Merck & Co. to explore treatments for cognitive decline linked to Alzheimer's disease. Formerly known as Bionomics Limited, the company rebranded in December 2024 and is headquartered in Burlington, Massachusetts.
